噻托溴铵联合布地奈德福莫特罗粉吸入剂对重度支气管哮喘患者ACT评分及肺功能的影响  

Effect of Tiotropium Bromide Combined with Budesonide Formoterol Powder Inhaler on ACT Score and Lung Function in Patients with Severe Bronchial Asthma

作　　者：陈媛媛 牛莎[2] CHEN Yuanyuan;NIU Sha(Department of Respiratory and Critical Care Medicine,Yongcheng People's Hospital,Shangqiu 476600 China;Department of Respiratory and Critical Care Medicine,Jiaozuo Second People's Hospital,Jiaozuo 454000 China)

机构地区：[1]永城市人民医院呼吸与危重症医学科,河南商丘476600 [2]焦作市第二人民医院呼吸与危重症医学科,河南焦作454000

出　　处：《内蒙古医学杂志》2023年第7期808-811,共4页Inner Mongolia Medical Journal

摘　　要：目的研究噻托溴铵联合布地奈德福莫特罗粉吸入剂对重度支气管哮喘患者哮喘控制测试评分(ACT)及肺功能的影响。方法以2019年7月至2022年7月我院收治的102例重度支气管哮喘患者为研究对象,采用随机数表法将患者分为对照组和联合组,每组51例。对照组采用布地奈德福莫特罗粉吸入剂治疗,联合组采用噻托溴铵联合布地奈德福莫特罗粉吸入剂治疗。比较两组临床疗效、治疗前及治疗4周后ACT评分、急性加重频率、肺功能指标[第1s用力呼吸容积(FEV1)、FEV1占用力肺活量(FVC)百分比(FEV1/FVC)、呼气峰流速值(PEF)]、血清炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-18(IL-18)、超敏C反应蛋白(hs-CRP)]水平、不良反应发生率。结果联合组临床总有效率为96.08%(49/51),高于对照组的82.35%(42/51)(P<0.05);治疗4周后联合组ACT评分高于对照组,急性加重频率低于对照组(P<0.05);治疗4周后联合组FEV1、FEV1/FVC、PEF高于对照组(P<0.05);治疗4周后联合组血清IL-6、TNF-α、IL-18、hs-CRP水平低于对照组(P<0.05);联合组不良反应总发生率为7.84%(4/51),与对照组的3.92%(2/51)相比,差异无统计学意义(P>0.05)。结论噻托溴铵联合布地奈德福莫特罗粉吸入剂治疗重度支气管哮喘疗效显著,可有效缓解症状,改善肺功能,促进康复。Objective To investigate the effects of tiotropium bromide combined with budesonide for-moterol powder inhalation on asthma control test score(ACT)and lung function in patients with severe bronchial asthma.Methods A total of 102 patients with severe bronchial asthma admitted to our hospital from July 2019 to July 2022 were selected as research objects.The patients were divided into control group and com-bination group by random number table method,with 51 cases in each group.To compare the clinical efficacy,ACT score before and after 4 weeks of treatment,frequency of acute exacerbations,pulmonary function indexes[first second exertional volume of breath(FEV1),FEV1 as a percentage of exertional lung volume(FVC)(FEV1/FVC),peak expiratory flow rate value(PEF)],serum inflammatory factors[interleukin-6(IL-6),tumour necrosis factor-α(TNF-α),interleukin-18(IL-18),hypersensitive C-reactive protein(hs-CRP)]Jlevels and incidence of adverse reactions between the two groups.Results The total effective rate of com-bined group was 96.08%(49/51)higher than that of control group 82.35%(42/51)(P<0.05).After 4 weeks of treatment,the ACT score of the combination group was higher than that of the control group,and the fre-quency of acute exacerbation was lower than that of the control group(P<0.05).After 4 weeks of treatment,FEV1,FEV1/FVC and PEF in combination group were higher than those in control group(P<0.05);After 4 weeks of treatment,the serum levels of IL-6 and TNF-αIL-18、hs-CRP incombinationgroupwerelower than those in control group(P<0.05).The total incidence of adverse reactions in the combined group was 7.84%(4/51)compared with 3.92%(2/51)in the control group,with no statistical significance(P>0.05).Conclusion Tiotropium bromide combined with budesonide formoterol powder is effective in the treatment of severe bronchial asthma,which can effectively relieve symptoms,improve lung function and promote the recov-ery of the disease.

关 键 词：噻托溴铵粉吸入剂 布地奈德福莫特罗粉吸入剂 重度支气管哮喘 ACT评分 

分 类 号：R562.25[医药卫生—呼吸系统]